We are proud to see our CEO, Brian Stemme, featured in a BioCentury article highlighting Hoosier Cancer Research Network’s role in advancing multi-site investigator-initiated trials (IITs)-
In the article, Brian shares how HCRN helps bridge the gap between academia and industry by connecting investigators with the infrastructure and support needed to turn innovative clinical research ideas into reality.
At Hoosier Cancer Research Network, that same spirit of collaboration drives our mission to strengthen the academic research community, expand access to clinical trials, and generate real-world data that can make a difference for patients.
Read the article: https://www.biocentury.com/article/657162/how-multi-site-iits-can-help-bridge-the-academia-industry-gap
Listen to the BioCentury Podcast: https://www.biocentury.com/article/657192/pfizer-s-mfn-deal-new-trial-paradigm-tcg-x-s-1-3b-fund-a-biocentury-podcast
(Subscription may be required)
About Hoosier Cancer Research Network:
Hoosier Cancer Research Network conducts innovative cancer clinical trials in collaboration with more than 100 academic and community clinical research sites across the United States. Our studies are designed by cancer researchers from our member institutions. The HCRN staff includes 55 team members who work together to support all aspects of the studies we manage, from the time we receive the initial concept from a researcher through the final publication of the study results. Currently, we are supporting more than 70 clinical trials across a wide range of cancer types. Over our 40-year history, more than 10,000 participants have enrolled in our clinical trials, leading to important discoveries that help cancer patients live longer and better after their cancer diagnosis.
